Mitapivat
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease.
Journal: Blood. Red cells & iron
Published: March 11, 2026
Discovery of 8-quinolinesulfonamide phenylimidazole-based PKM2 agonists for the prevention and delay of aortic dissection.
Journal: European journal of medicinal chemistry
Published: September 24, 2025
Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study.
Journal: Haematologica
Published: September 02, 2025
The ENERGIZE trial: Is mitapivat ready to take center stage in NTDT management?
Journal: Med (New York, N.Y.)
Published: August 08, 2025
Efficacy and safety of Mitapivat in sickle cell disease: a systematic review.
Journal: Expert opinion on pharmacotherapy
Published: July 07, 2025
Potent Fluorescent Probe for Target-Engagement Studies of Allosteric Pyruvate Kinase Modulators.
Journal: Angewandte Chemie (International ed. in English)
Published: June 26, 2025
Metabolomics in sickle cell disease: Current knowledge and gaps - A scoping review.
Journal: Blood reviews
Published: June 25, 2025
Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review.
Efficacy and safety of pyruvate kinase activator in treating hemolytic anemias: a systematic review.
Journal: Expert review of hematology
Published: June 17, 2025
Fluorescent binding assay for allosteric ligands of liver pyruvate kinase.
Journal: European journal of medicinal chemistry
Published: May 09, 2025
Last Updated: 04/28/2026